RecruitingNCT03094429
Study of NaBen added to clozapine for resistant schizophrenia
About this title
Read the official source — NCT03094429This study evaluates the safety and effectiveness of NaBen® for people with schizophrenia.
Medication studyAges 18–55United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of NaBen® for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 55 years.
- Listed locations
- PasadenaSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 29, 2017
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 287
- Sponsor
- SyneuRx International (Taiwan) Corp
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03094429
- Official title
Show the full official title
An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Pasadena
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of NaBen® for people with schizophrenia.
Who is behind this study?
The study sponsor is SyneuRx International (Taiwan) Corp.
Does this study involve medication?
Yes. The study involves medication, including NaBen®.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
